Spontaneous and engineered compensatory HSV mutants that counteract the host antiviral PKR response

Viruses

Volumn 1, Issue 3, 2009, Pages 510-522

  Shah, Amish C ^a   Parker, Jacqueline N ^b   Shimamura, Masako ^b   Cassady, Kevin A ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

1134.5; Oncolytic HSV; PKR

Indexed keywords

EID: 77954910083     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v1030510     Document Type: Review

References (48)

1. Samuel, C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 2001, 14, 778-809, table of contents.
2. Katze, M. G. Regulation of the interferon-induced PKR: can viruses cope? Trends Microbiol. 1995, 3, 75-78.
3. Thomis, D.C.; Samuel, C.E. Mechanism of interferon action: evidence for intermolecular autophosphorylation and autoactivation of the interferon-induced, RNA-dependent protein kinase PKR. J. Virol. 1993, 67, 7695-7700.
4. Ortega, L.G.; McCotter, M.D.; Henry, G.L.; McCormack, S.J.; Thomis, D.C.; Samuel, C.E. Mechanism of interferon action. Biochemical and genetic evidence for the intermolecular association of the RNA-dependent protein kinase PKR from human cells. Virology 1996, 215, 31-39.
5. Williams, B.R. Signal integration via PKR. Sci. STKE 2001, 2001, RE2.
6. Smith, K.D.; Mezhir, J.J.; Bickenbach, K.; Veerapong, J.; Charron, J.; Posner, M.C.; Roizman, B.; Weichselbaum, R.R. Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J. Virol. 2006, 80, 1110-1120.
7. Silva, A.M.; Whitmore, M.; Xu, Z.; Jiang, Z.; Li, X.; Williams, B.R. Protein kinase R (PKR) interacts with and activates mitogen-activated protein kinase kinase 6 (MKK6) in response to double-stranded RNA stimulation. J. Biol. Chem. 2004, 279, 37670-37676.
8. Talloczy, Z.; Jiang, W.; Virgin, H.W., IV; Leib, D.A.; Scheuner, D.; Kaufman, R.J.; Eskelinen, E.L.; Levine, B. Regulation of starvation-and virus-induced autophagy by the eIF2alpha kinase signaling pathway. Proc. Natl. Acad. Sci. U S A 2002, 99, 190-195.
9. Franklin, J.L.; Johnson, E.M. Control of neuronal size homeostasis by trophic factor-mediated coupling of protein degradation to protein synthesis. J. Cell Biol. 1998, 142, 1313-1324.
10. Williams, B.R. PKR: a sentinel kinase for cellular stress. Oncogene 1999, 18, 6112-6120.
11. Chou, J.; Chen, J.J.; Gross, M.; Roizman, B. Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5-mutants of herpes simplex virus 1. Proc. Natl. Acad. Sci. U S A 1995, 92, 10516-10520.
12. Chou, J.; Kern, E.R.; Whitley, R.J.; Roizman, B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990, 250, 1262-1266.
13. He, B.; Chou, J.; Liebermann, D.A.; Hoffman, B.; Roizman, B. The carboxyl terminus of the murine MyD116 gene substitutes for the corresponding domain of the gamma(1)34.5 gene of herpes simplex virus to preclude the premature shutoff of total protein synthesis in infected human cells. J. Virol. 1996, 70, 84-90.
14. He, B.; Gross, M.; Roizman, B. The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. U S A 1997, 94, 843-848.
15. Zhan, Q.; Lord, K.A.; Alamo, I., Jr.; Hollander, M.C.; Carrier, F.; Ron, D.; Kohn, K.W.; Hoffman, B.; Liebermann, D.A.; Fornace, A.J., Jr. The gadd and MyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth. Mol. Cell Biol. 1994, 14, 2361-2371.
16. Chou, J.; Roizman, B. The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc. Natl. Acad. Sci. U S A 1992, 89, 3266-3270.
17. Cheng, G.; Yang, K.; He, B. Dephosphorylation of eIF-2alpha mediated by the gamma(1)34.5 protein of herpes simplex virus type 1 is required for viral response to interferon but is not sufficient for efficient viral replication. J. Virol. 2003, 77, 10154-10161.
18. Cassady, K.A.; Gross, M.; Gillespie, G.Y.; Roizman, B. Second-site mutation outside of the U(S)10-12 domain of Deltagamma(1)34.5 herpes simplex virus 1 recombinant blocks the shutoff of protein synthesis induced by activated protein kinase R and partially restores neurovirulence. J. Virol. 2002, 76, 942-949.
19. Harle, P.; Cull, V.; Agbaga, M.P.; Silverman, R.; Williams, B.R.; James, C.; Carr, D.J. Differential effect of murine alpha/beta interferon transgenes on antagonization of herpes simplex virus type 1 replication. J. Virol. 2002, 76, 6558-6567.
20. Yokota, S.; Yokosawa, N.; Okabayashi, T.; Suzutani, T.; Miura, S.; Jimbow, K.; Fujii, N. Induction of suppressor of cytokine signaling-3 by herpes simplex virus type 1 contributes to inhibition of the interferon signaling pathway. J. Virol. 2004, 78, 6282-6286.
21. Markovitz, N.S.; Baunoch, D.; Roizman, B. The range and distribution of murine central nervous system cells infected with the gamma(1)34.5-mutant of herpes simplex virus 1. J. Virol. 1997, 71, 5560-5569.
22. Andreansky, S.S.; He, B.; Gillespie, G.Y.; Soroceanu, L.; Markert, J.; Chou, J.; Roizman, B.; Whitley, R.J. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc. Natl. Acad. Sci. U S A 1996, 93, 11313-11318.
23. Shah, A.C.; Parker, J.N.; Gillespie, G.Y.; Lakeman, F.D.; Meleth, S.; Markert, J.M.; Cassady, K.A. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses. Gene Ther. 2007, 14, 1045-1054.
24. Orvedahl, A.; Alexander, D.; Talloczy, Z.; Sun, Q.; Wei, Y.; Zhang, W.; Burns, D.; Leib, D.A.; Levine, B. HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. Cell Host Microbe 2007, 1, 23-35.
25. Cobbs, C.; Markert, J. Gene Therapy of Glioma: A Review. Perspectives in Neurological Surgery 1999, in press.
26. Markert, J.M.; Gillespie, G.Y.; Weichselbaum, R.R.; Roizman, B.; Whitley, R.J. Genetically engineered HSV in the treatment of glioma: a review. Rev. Med. Virol. 2000, 10, 17-30.
27. Rampling, R.; Cruickshank, G.; Papanastassiou, V.; Nicoll, J.; Hadley, D.; Brennan, D.; Petty, R.; MacLean, A.; Harland, J.; McKie, E.; Mabbs, R.; Brown, M. Toxicity evaluation of replication competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 2000, 7, 859-866.
28. Bower, J.R.; Mao, H.; Durishin, C.; Rozenbom, E.; Detwiler, M.; Rempinski, D.; Karban, T.L.; Rosenthal, K.S. Intrastrain variants of herpes simplex virus type 1 isolated from a neonate with fatal disseminated infection differ in the ICP34.5 gene, glycoprotein processing, and neuroinvasiveness. J. Virol. 1999, 73, 3843-3853.
29. Mao, H.; Rosenthal, K.S. Strain-dependent structural variants of herpes simplex virus type 1 ICP34.5 determine viral plaque size, efficiency of glycoprotein processing, and viral release and neuroinvasive disease potential. J. Virol. 2003, 77, 3409-3417.
30. Verpooten, D.; Ma, Y.; Hou, S.; Yan, Z.; He, B. Control of TANK-binding kinase 1-mediated signaling by the gamma(1)34.5 protein of herpes simplex virus 1. J. Biol. Chem. 2009, 284, 1097-1105.
31. Mohr, I.; Gluzman, Y. A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. Embo J. 1996, 15, 4759-4766.
32. Cassady, K.A.; Gross, M.; Roizman, B. The herpes simplex virus US11 protein effectively compensates for the gamma1(34.5) gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation factor 2. J. Virol. 1998, 72, 8620-8626.
33. Cassady, K.A.; Gross, M.; Roizman, B. The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha. J. Virol. 1998, 72, 7005-7011.
34. Mohr, I.; Sternberg, D.; Ward, S.; Leib, D.; Mulvey, M.; Gluzman, Y. A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J. Virol. 2001, 75, 5189-5196.
35. Taneja, S.; MacGregor, J.; Markus, S.; Ha, S.; Mohr, I. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc. Natl. Acad. Sci. U S A 2001, 98, 8804-8808.
36. Shah, A.C.; Price, K.H.; Parker, J.N.; Samuel, S.L.; Meleth, S.; Cassady, K.A.; Gillespie, G.Y.; Whitley, R.J.; Markert, J.M. Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors. J. Virol. 2006, 80, 7308-7315.
37. Todo, T.; Martuza, R.L.; Rabkin, S.D.; Johnson, P.A. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. U S A 2001, 98, 6396-6401.
38. Liu, R.; Martuza, R.L.; Rabkin, S.D. Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene Ther. 2005, 12, 647-654.
39. Fukuhara, H.; Martuza, R.L.; Rabkin, S.D.; Ito, Y.; Todo, T. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin. Cancer Res. 2005, 11, 7886-7890.
40. Messerli, S.M.; Prabhakar, S.; Tang, Y.; Mahmood, U.; Giovannini, M.; Weissleder, R.; Bronson, R.; Martuza, R.; Rabkin, S.; Breakefield, X.O. Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Hum. Gene Ther. 2006, 17, 20-30.
41. Chung, R.Y.; Saeki, Y.; Chiocca, E.A. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J. Virol. 1999, 73, 7556-7564.
42. Nakamura, H.; Kasuya, H.; Mullen, J.T.; Yoon, S.S.; Pawlik, T.M.; Chandrasekhar, S.; Donahue, J.M.; Chiocca, E.A.; Chung, R.Y.; Tanabe, K.K. Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J. Clin. Invest. 2002, 109, 871-882.
43. Kanai, R.; Tomita, H.; Shinoda, A.; Takahashi, M.; Goldman, S.; Okano, H.; Kawase, T.; Yazaki, T. Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence. Gene Ther. 2006, 13, 106-116.
44. Kambara, H.; Okano, H.; Chiocca, E.A.; Saeki, Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res. 2005, 65, 2832-2839.
45. Zhou, G.; Ye, G.J.; Debinski, W.; Roizman, B. Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc. Natl. Acad. Sci. U S A 2002, 99, 15124-15129.
46. Zhou, G.; Roizman, B. Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells. J. Virol. 2005, 79, 5272-5277.
47. Child, S.J.; Hakki, M.; De Niro, K.L.; Geballe, A.P. Evasion of cellular antiviral responses by human cytomegalovirus TRS1 and IRS1. J. Virol. 2004, 78, 197-205.
48. Cassady, K.A. Human cytomegalovirus TRS1 and IRS1 gene products block the double-stranded-RNA-activated host protein shutoff response induced by herpes simplex virus type 1 infection. J. Virol. 2005, 79, 8707-8715.